基本信息
浏览量:0
职业迁徙
个人简介
Clinical Trials and Research Studies
A Phase 1 Open-label Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High Risk Newly Diagnosed Multiple Myelorna (NDMM) (KarMMa-4)
A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
A PHASE Ib STUDY EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF VENETOCLAX IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB (R) AND CYCLOPHOSPHAMIDE DOXORUBICIN PREDNISONE (CHP) IN PATIENTS WITH UNTREATED BCL-2 IMMUNOHISTOCHEMISTRY (IHC) POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
A Phase 1 Open-label Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High Risk Newly Diagnosed Multiple Myelorna (NDMM) (KarMMa-4)
A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
A PHASE Ib STUDY EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF VENETOCLAX IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB (R) AND CYCLOPHOSPHAMIDE DOXORUBICIN PREDNISONE (CHP) IN PATIENTS WITH UNTREATED BCL-2 IMMUNOHISTOCHEMISTRY (IHC) POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
研究兴趣
论文共 7 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Catherine Diefenbach,Bruce G. Raphael,Michael L. Grossbard,Kenneth B. Hymes,Tibor Moskovits,David Kaminetzky,Peter Martin,Jia Ruan, Megan McShea, Leonelle B'etou,Maryam Bonakdar,Cem Abidoglu,
Catherine S. Diefenbach,Bruce Raphael,Kenneth B. Hymes,Tibor Moskovits,David Kaminetzky,Peter Martin,Jia Ruan,Stephanie Lauro, Danielle Banks, Krysten Brown,Maryam Bonakdar,Cem Abidoglu,
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn